Non Small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
Nitroglycerin as a Sensitizer in the Treatment of Non Small Cell Lung Cancer: a Phase II Trial
Nitroglycerin is a nitric oxide donor which is mainly known as a vasodilating agent used in
ischemic heart disease. It has also been shown to increase tumor blood flow in animal and
human tumors.
The addition of nitroglycerin to chemotherapy in non small cell lung cancer has been shown to
generate very favorable response rates with respect to standard treatment schedules[5].
Theoretically nitroglycerin might reduce resistance to chemotherapy via a plethora of
different effects: better tumor perfusion, direct effects of NO on cancer cells, increase in
activated p53 protein and via an increased blood flow in the tumour with as consequence a
higher drug concentration in the tumor [6] .
In mice, nitric oxide donors such as isosorbide dinitrate have been shown to decrease tumor
hypoxia by better tumor perfusion, which could enhance radiotherapy responses [7].
To date these combined effects have not been tested in humans. In this trial we would like to
demonstrate the effect of nitroglycerin on tumor perfusion and hypoxia in non small cell lung
cancer (using DCE and HX4 scanning), providing a rationale for further study and to test the
effect of combining nitroglycerine to standard treatment of NSCLC
(radiotherapy/chemotherapy).
Namely, the failure of many different tumor types to show a lasting response chemotherapy or
radiotherapy might be attributable to a lack of oxygen supply (called "hypoxia" from hereon)
in a large part of the cancer cells.
Tumor hypoxia is a well-known factor negatively influencing outcome in many solid tumors,
including lung cancer, head and neck cancer, etc. Hypoxic cells are more radio-resistant,
more chemo-resistant and more prone to develop distant metastases than normoxic cells.
Nitroglycerin, due to it`s vasoactive effects, tends to redistribute the blood supply to the
tumor, increasing tumor blood flow, hereby theoretically decreasing hypoxia.
It has been shown that NO donating drugs can alter tumor blood flow and oxygenation status in
animal models [7]. In a randomized phase 2 trial by Yasuda nitroglycerin has been
successfully combined at a dose of 25 mg daily for 5 days each chemo cycle with cisplatin and
vinorelbine in non small cell lung cancer, enhancing chemotherapy response, possibly due to
better delivery of the anti-cancer drugs in the tumor[5]. The toxicity profile between the 2
arms was not significantly different.
The effects of nitroglycerin or other donating drugs on cancer have been found to be
numerous: not only is there an increase in tumor bloodflow, also direct effects on
stabilization of p53 and degradation of Hif-1 alpha have been found[6]. Decreased hypoxic
biomarkers (eg VEGF, P-glycoprotein) have been found in patients with NSCLC treated with
nitroglycerin patches for 3 days prior to surgery when compared to non-treated individuals
[8]. There might also be a supplementary effect on the MHC-molecules, rendering tumor cells
more "visible" to the immune system [9].
Furthermore, hypoxia has been shown in vitro to increase the invasiveness of cancer cells in
an NO-mediated manner, which can be blocked by NO-donors.[10] An interesting study in this
respect is a non-randomized phase 2 trial by Siemens et al, in which a very low dose of
nitroglycerin (Minitran 5 patch (18 mg) cut in 6 pieces, delivering 0.033 mg/h in stead of
0.2 mg/h normally) was given to patients with biochemical recurrence (PSA-failure) after
primary therapy. After 24 months the PSA doubling time was more than 31 months versus 12.8
months before the start of therapy, demonstrating the inhibitory effect of nitroglycerin on
prostate cancer cells. [11]
Due to these effects and the effect on tumor bloodflow and decrease of hypoxia nitroglycerin
might also be interesting as a radiosensitizing agent.
Currently a Mexican phase 2 trial is recruiting 40 patients to evaluate the efficacy of
nitroglycerin added to concurrent chemoradiotherapy in NSCLC stage III. (Clinical trials.gov
identifier NCT00886405).
The aim of the present study is not only to demonstrate the effect of nitroglycerin on
perfusion and hypoxia through (HX4-)scanning of patients, but also documenting the efficacy
of the approach of giving nitroglycerin in an on/off (12h/12h) schedule to people receiving
(chemo-)/radiotherapy, whilst monitoring toxicity.
The on-off schedule is chosen because of the existence of a tolerance effect on the vascular
system, hence diminishing the effect of nitroglycerin already after the first 24 hours.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01204099 -
Study of PX-866 and Docetaxel in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00148798 -
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
|
Phase 3 | |
Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02988817 -
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01005797 -
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
|
Phase 1 | |
Recruiting |
NCT00637910 -
Tarceva Italian Lung Optimization tRial
|
Phase 3 | |
Active, not recruiting |
NCT03447678 -
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
|
Phase 2 | |
Completed |
NCT02456246 -
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
|
N/A | |
Terminated |
NCT01741155 -
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT02014324 -
Single Scope Staging of Lung Cancer With Endosonography
|
N/A | |
Completed |
NCT01594398 -
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01323062 -
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04772989 -
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01702844 -
Single Arm on the Tolerability of Weekly Nab-paclitaxel
|
Phase 2 | |
Completed |
NCT00492206 -
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
|
Phase 2 | |
Completed |
NCT00820417 -
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
|
Phase 1 | |
Completed |
NCT02639026 -
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
|
Phase 1 | |
Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
Active, not recruiting |
NCT04721015 -
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
|
Phase 1 |